Optimizing esketamine administration for postoperative depression: a comprehensive study on laparoscopic bariatric surgery patients.

Jiabao Dai, Yanfeng Lu, Zhiqing Zou, Zhouquan Wu
Author Information
  1. Jiabao Dai: Department of Anesthesiology, the NO.2 People's Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China.
  2. Yanfeng Lu: Department of Anesthesiology, the NO.2 People's Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China.
  3. Zhiqing Zou: Department of Anesthesiology, the NO.2 People's Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China.
  4. Zhouquan Wu: Department of Anesthesiology, the NO.2 People's Hospital of Changzhou Affiliated to Nanjing Medical University, Changzhou, China. wuzhouquan2005@126.com.

Abstract

BACKGROUND: Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive effects of subanesthetic doses esketamine have been observed in treatment-resistant depression, the response to this medication in patients experiencing depression following surgery has not been consistent. Building upon the known impact of anesthesia on brain function, we have formulated a hypothesis suggesting that the timing of esketamine administration in relation to anesthesia may significantly affect its efficacy in managing postoperative depression. The aim of this study was to investigate the effect of esketamine administered at different time points before and after anesthesia.
METHODS: Our randomized, double-blind, controlled study involved 120 patients undergoing laparoscopic bariatric surgery, randomly divided into three groups. Group Post- ESK received an intravenous injection of esketamine at a dose of 0.2 mg/kg after anesthesia induction. Group Pre- ESK received the same esketamine dosage 2 h prior to anesthesia induction. Group Placebo served as the control group and received a 0.9% saline solution after induction. The primary outcome measures of the study were depression scores as measured by Patient Health Questionnaire-9 (PHQ-9) and plasma brain-derived neurotrophic factor (BDNF) levels.
RESULTS: On the first postoperative day, the PHQ-9 scores, incidence and severity of postoperative depression in the Pre-ESK group were significantly lower than those in the Post-ESK and placebo groups (P < 0.05). Additionally, plasma BDNF levels in the Pre-ESK group were significantly higher than those in the Post-ESK and placebo groups (P < 0.05). Notably, there was a negative correlation between PHQ-9 scores and plasma BDNF levels.
CONCLUSIONS: Our study supports the potential for subanesthetic dose esketamine to alleviate postoperative depression symptoms following laparoscopic bariatric surgery, and anesthetic drugs have a significant effect on its efficacy. The use of subanesthetic dose esketamine after anesthesia does not improve postoperative depression symptoms in patients undergoing laparoscopic bariatric surgery, while the use of sub-anesthetic dose esketamine before anesthesia can improve postoperative depression symptoms.

Keywords

References

  1. Rev Neurosci. 2017 Jul 26;28(5):499-508 [PMID: 28306543]
  2. Anesth Analg. 2002 Nov;95(5):1274-81, table of contents [PMID: 12401610]
  3. Obes Surg. 2021 May;31(5):1937-1948 [PMID: 33432483]
  4. Br J Anaesth. 2022 Jun;128(6):1019-1028 [PMID: 35164969]
  5. Expert Opin Drug Saf. 2022 Jun;21(6):777-787 [PMID: 35416105]
  6. Anesth Analg. 2010 Jun 1;110(6):1607-13 [PMID: 20435940]
  7. Br J Anaesth. 2024 Feb;132(2):224-226 [PMID: 38092601]
  8. Science. 2023 Dec 22;382(6677):1389-1394 [PMID: 38060673]
  9. Am J Psychiatry. 2021 Dec;178(12):1130 [PMID: 34855448]
  10. Pharmaceuticals (Basel). 2023 May 12;16(5): [PMID: 37242525]
  11. J Am Heart Assoc. 2022 May 3;11(9):e024377 [PMID: 35470691]
  12. Br J Anaesth. 2024 Feb;132(2):334-342 [PMID: 38044237]
  13. Front Pharmacol. 2020 Feb 06;10:1702 [PMID: 32116688]
  14. eNeuro. 2020 Feb 28;7(1): [PMID: 32019872]
  15. Psychosomatics. 2020 Sep - Oct;61(5):498-507 [PMID: 32451127]
  16. Prog Neurobiol. 2010 Dec;92(4):601-12 [PMID: 20727935]
  17. JAMA Psychiatry. 2018 Feb 1;75(2):139-148 [PMID: 29282469]
  18. Br J Anaesth. 1983 Mar;55(3):201-7 [PMID: 6131686]
  19. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111033 [PMID: 38788892]
  20. Ann Thorac Surg. 2021 Mar;111(3):1064-1070 [PMID: 32707196]
  21. Magn Reson Med. 2019 Jul;82(1):84-94 [PMID: 30860289]
  22. J Affect Disord. 2022 Jun 15;307:97-107 [PMID: 35378150]
  23. Nat Ment Health. 2023 Nov;1(11):876-886 [PMID: 38188539]
  24. Transl Psychiatry. 2019 Nov 7;9(1):280 [PMID: 31699965]
  25. J Neurol Sci. 2022 Mar 15;434:120152 [PMID: 35092901]
  26. Cell Rep. 2018 Jan 9;22(2):427-440 [PMID: 29320738]
  27. Biomolecules. 2023 Feb 15;13(2): [PMID: 36830736]
  28. Biol Psychiatry. 2016 Sep 15;80(6):424-431 [PMID: 26707087]
  29. Br J Anaesth. 2018 Nov;121(5):1075-1083 [PMID: 30336852]
  30. Expert Rev Clin Pharmacol. 2021 Jan;14(1):25-32 [PMID: 33225765]
  31. J Surg Oncol. 2019 Sep;120(3):389-396 [PMID: 31209894]

Grants

  1. CMCC202214/Research project of Changzhou Medical Center

MeSH Term

Humans
Ketamine
Double-Blind Method
Male
Female
Adult
Middle Aged
Brain-Derived Neurotrophic Factor
Bariatric Surgery
Laparoscopy
Depression
Postoperative Complications
Antidepressive Agents
Treatment Outcome

Chemicals

Ketamine
Esketamine
Brain-Derived Neurotrophic Factor
BDNF protein, human
Antidepressive Agents

Word Cloud

Created with Highcharts 10.0.0esketaminedepressionpostoperativeanesthesiasurgerystudybariatricpatientslaparoscopicdoseefficacysubanestheticsignificantlygroupsGroupreceivedinductiongroupscoresPHQ-9plasmaBDNFlevelssymptomsmanagingfollowingadministrationeffectundergoingESK0Pre-ESKPost-ESKplaceboP < 005useimproveBACKGROUND:Previousstudiesreportedconflictingfindingsregardingpositiveeffectsdosesobservedtreatment-resistantresponsemedicationexperiencingconsistentBuildinguponknownimpactbrainfunctionformulatedhypothesissuggestingtimingrelationmayaffectaiminvestigateadministereddifferenttimepointsMETHODS:randomizeddouble-blindcontrolledinvolved120randomlydividedthreePost-intravenousinjection2 mg/kgPre-dosage2 hpriorPlaceboservedcontrol9%salinesolutionprimaryoutcomemeasuresmeasuredPatientHealthQuestionnaire-9brain-derivedneurotrophicfactorRESULTS:firstdayincidenceseveritylowerAdditionallyhigherNotablynegativecorrelationCONCLUSIONS:supportspotentialalleviateanestheticdrugssignificantsub-anestheticcanOptimizingdepression:comprehensiveAnesthesiaAntidepressantEsketamineLaparoscopic

Similar Articles

Cited By

No available data.